Still reeling from Zejula setback, GlaxoSmithKline gets a breather with expanded PD-1 approval

Max Gelman

Senior Editor

A little less than four months ago, GlaxoSmithKline shepherded the seventh PD-1 across the finish line in Jemperli, winning accelerated approval for a specific …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Still reeling from Zejula setback, GlaxoSmithKline gets a breather with expanded PD-1 approval

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Still reel­ing from Ze­ju­la set­back, Glax­o­SmithK­line gets a breather with ex­pand­ed PD-1 ap­proval

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Still reeling from Zejula setback, GlaxoSmithKline gets a breather with expanded PD-1 approval

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial